i
Use of Pfizer-BioNTech COVID-19 vaccine in persons aged ≥16 years: recommendations of the Advisory Committee on Immunization Practices — United States, September 2021
-
September 21, 2021
Details:
-
Personal Author:
-
Corporate Authors:United States. Advisory Committee on Immunization Practices. ; CDC COVID-19 Response Team. ; Centers for Disease Control and Prevention (U.S.). Epidemic Intelligence Service. ; University of Arizona. College of Medicine. ; McMaster University. Faculty of Health Sciences. Department of Health Research Methods, Evidence, and Impact. ; ... More +
-
Description:What is already known about this topic? On August 23, 2021, the Food and Drug Administration granted full approval of the Pfizer-BioNTech COVID-19 vaccine for persons aged ≥16 years.
What is added by this report? On August 30, 2021, after a systematic review of the data, the Advisory Committee on Immunization Practices revised its interim recommendation to a standard recommendation for use of the Pfizer-BioNTech COVID-19 vaccine in persons aged ≥16 years for the prevention of COVID-19.
What are the implications for public health practice? Continued use of the Pfizer-BioNTech COVID-19 vaccine, now fully approved by the FDA in persons aged ≥16 years, is recommended based on increased certainty that its benefits (prevention of asymptomatic infection, COVID-19, and associated hospitalization and death) outweigh vaccine-associated risks. Suggested citation for this article: Self WH, Tenforde Suggested citation for this article: Dooling K, Gargano JW, Moulia D, et al. Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2021. MMWR Morb Mortal Wkly Rep. ePub: 21 September 2021.
mm7038e2.htm?s_cid=mm7038e2_w#contribAff
mm7038e2-H.pdf
-
Subjects:
-
Document Type:
-
Name as Subject:
-
Location:
-
Collection(s):
-
Main Document Checksum:
-
File Type: